Nivolumab (Opdivo) plus ipilimumab (Yervoy) showed significant activity in patients with advanced gynecologic clear cell carcinomas, according to results from a phase II nonrandomized trial. Among 26 ...

Gynecological clear cell cancers (CCCs), very aggressive forms of ovarian and endometrial malignancies, respond poorly to chemotherapy. The low response rates underscore a significant clinical need to ...

Lurie Cancer Center initiates trial combining LIXTE's LB-100 and GSK's Dostarlimab for ovarian clear cell cancer treatment. LIXTE Biotechnology Holdings, Inc. has announced that the Robert H. Lurie ...

“Continued progress has been made in collaborative clinical studies with two global pharmaceutical companies for our lead proprietary compound, LB-100, to treat ovarian and colorectal cancer,” said ...

The Phase 1b Clinical Trial Focuses on Assessing the Safety and Efficacy of the Two-Drug Combination in a Cancer Associated with Longer Survival to Immunotherapy When Genetically Deficient in PP2A ...

For the purpose of guiding the choice of second-line chemotherapy, the time to relapse after initial chemotherapy is empirically divided into 6-month blocks. Patients who relapse during or immediately ...

More than 300,000 women are diagnosed with ovarian cancer globally each year. The four-year clinical trial across 15 ...

Ovarian cancer is a condition that starts in the reproductive glands responsible for producing eggs and hormones in people assigned female at birth. In its early stages, it often develops without ...

-Started Two New Clinical Trials, Collaborating with MD Anderson and The Netherlands Cancer Institute for Treatment of Ovarian and Colorectal Cancer- -Received Exclusive Patent License Agreement with ...